» Articles » PMID: 8581559

An Endogenous Dopaminergic Neurotoxin: Implication for Parkinson's Disease

Overview
Specialty Neurology
Date 1995 Sep 1
PMID 8581559
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidation of dopamine by monoamine oxidase results in the endogenous metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). The toxicity of DOPAL for dopaminergic neurons was investigated using rat neostriatal synaptosomes, PC-12 cells and cultures of fetal rat dissociated mesencephalon. The Na(+)-dependent uptake of [3H]DOPAL in synaptosomes was inhibited by mazindol. DOPAL selectively inhibited dopamine uptake but not [14C]GABA uptake, induced membrane damage and liberation of dopamine into the medium. Incubation of PC-12 cells with 6.5 microM of DOPAL for 24 h caused degeneration of the neuritic process, and the number of viable cells were reduced by 25% of control. There were practically no surviving cells after 24 h of incubation with 33 microM of DOPAL. After 8 h of treatment with 33 microM of DOPAL, dopamine and 3,4-dihydroxyphenylacetic acid content in the cells were reduced by 38% and 53% of control. DOPAL-induced cell damage released lactic acid dehydrogenase into the incubation media. This toxic effect of DOPAL was time- and concentration-dependent. In mesencephalic cultures, after exposure to 33 microM of DOPAL, the surviving TH+ cells showed rounded cell body, and fibre network was highly reduced. These results indicate DOPAL is a neurotoxin and may be involved in the degeneration of dopaminergic neurons.

Citing Articles

Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature.

Ramesh S, Perera Molligoda Arachchige A AIMS Neurosci. 2023; 10(3):200-231.

PMID: 37841347 PMC: 10567584. DOI: 10.3934/Neuroscience.2023017.


Disruption of Dopamine Homeostasis Associated with Alteration of Proteins in Synaptic Vesicles: A Putative Central Mechanism of Parkinson's Disease Pathogenesis.

Jin X, Si X, Lei X, Liu H, Shao A, Li L Aging Dis. 2023; 15(3):1204-1226.

PMID: 37815908 PMC: 11081171. DOI: 10.14336/AD.2023.0821-2.


A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.

Fishman-Jacob T, Youdim M J Neural Transm (Vienna). 2023; 131(6):675-707.

PMID: 37644186 PMC: 11192832. DOI: 10.1007/s00702-023-02687-6.


Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.

Khashab R, Gutman-Sharabi N, Shabtai Z, Landau R, Halperin R, Fay-Karmon T Int J Mol Sci. 2023; 24(15).

PMID: 37569897 PMC: 10419703. DOI: 10.3390/ijms241512522.


Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases.

Goldstein D, Pekker M, Sullivan P, Isonaka R, Sharabi Y J Am Heart Assoc. 2022; 11(11):e024411.

PMID: 35621196 PMC: 9238705. DOI: 10.1161/JAHA.121.024411.